Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP6V1B1 | P15313 | 5/20 | 0.80 |
| ▸ | ATP6AP1 | Q15904 | 1/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1229725 | 1.00 | ATP6V1B1 (0.80) | ATP6V1B1ATP6AP1HDAC4HDAC6 | |
| SCHEMBL6296395 | 1.00 | ATP6V1B1 (0.80) | ATP6V1B1ATP6AP1HDAC4HDAC6 | |
| SCHEMBL6296361 | 1.00 | ATP6V1B1 (0.80) | ATP6V1B1ATP6AP1HDAC4HDAC6 | |
| SCHEMBL1229727 | 1.00 | ATP6V1B1 (0.80) | ATP6V1B1ATP6AP1HDAC4HDAC6 | |
| SCHEMBL29546820 | 1.00 | ATP6V1B1 (0.80) | ATP6V1B1ATP6AP1HDAC4HDAC6 | |
| SCHEMBL2400959 | 0.90 | ATP6V1B1 (0.64) | ATP6V1B1ATP6AP1HDAC4HDAC6 | |
| SCHEMBL2400947 | 0.90 | ATP6V1B1 (0.64) | ATP6V1B1ATP6AP1HDAC4HDAC6 | |
| SCHEMBL2400954 | 0.90 | ATP6V1B1 (0.64) | ATP6V1B1ATP6AP1HDAC4HDAC6 | |
| SCHEMBL6295642 | 0.86 | ATP6V1B1 (0.59) | ATP6V1B1ATP6AP1HDAC4HDAC6 | |
| SCHEMBL6291994 | 0.86 | ATP6V1B1 (0.60) | ATP6V1B1ATP6AP1HDAC4HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210402002-A1 | CONJUGATE | GLYKOS BIOMEDICAL OY (FI) | 2021-12-30 | — | — | US | claimed |
| US-20070299084-A1 | Indole Derivatives Useful for Treating Resistance to Antitumor Agents | NIKEM RESE S.R.L. (IT) | 2007-12-27 | — | — | US | claimed |
| EP-1753420-A1 | INDOLE DERIVATIVES USEFUL FOR TREATING RESISTANCE TO ANTITUMOUR AGENTS | NIKEM RESEARCH S.R.L. (IT) | 2007-02-21 | — | — | EP | claimed |
| WO-2005105078-A1 | INDOLE DERIVATIVES USEFUL FOR TREATING RESISTANCE TO ANTITUMOUR AGENTS | NIKEM RESEARCH S.R.L. (IT) | 2005-11-10 | — | — | WO | claimed |
| US-6903117-B2 | Indole derivatives for the treatment of osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2005-06-07 | — | — | US | claimed |
| EP-0914321-B1 | INDOLE DERIVATIVES FOR THE TREATMENT OF OSTEOPOROSIS | NIKEM RESEARCH SRL (IT) | 2004-09-22 | — | — | EP | claimed |
| US-20220243177-A1 | METHODS OF CULTURING QUIESCENT HEMATOPOIETIC STEM CELLS AND TREATMENT METHODS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-08-04 | — | — | US | disclosed |
| US-20210402002-A1 | CONJUGATE | GLYKOS BIOMEDICAL OY (FI) | 2021-12-30 | — | — | US | disclosed |
| CN-112672764-A | Conjugates | 格莱科斯生物医药公司 | 2021-04-16 | — | — | CN | disclosed |
| US-20110038852-A1 | ANTIVIRALS THAT TARGET TRANSPORTERS, CARRIERS, AND ION CHANNELS | 3-V BIOSCIENCES, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-6903117-B2 | Indole derivatives for the treatment of osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2005-06-07 | — | — | US | disclosed |
| EP-0914321-B1 | INDOLE DERIVATIVES FOR THE TREATMENT OF OSTEOPOROSIS | NIKEM RESEARCH SRL (IT) | 2004-09-22 | — | — | EP | disclosed |
| US-20040010012-A1 | Selective inhibitor of the biological activity of human osteoclast cells | SMITHKLINE BEECHAM SPA | 2004-01-15 | — | — | US | disclosed |
| US-20020173659-A1 | Indole derivatives for the treatment of osteoporosis | SMITH KLINE BEECHAM SPA | 2002-11-21 | — | — | US | disclosed |
| EP-0914321-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF OSTEOPOROSIS | Smithkline Beecham S.p.A. (IT) | 1999-05-12 | — | — | EP | disclosed |
| WO-1998001443-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF OSTEOPOROSIS | SMITHKLINE BEECHAM S.P.A. (IT) | 1998-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010012-A1 | Selective inhibitor of the biological activity of human osteoclast cells | HRH4, HRH3, CNKSR1 | ATP6V1B1 2556/4885ATP6AP1 2965/4885HDAC4 200/4885 |
| US-20070299084-A1 | Indole Derivatives Useful for Treating Resistance to Antitumor Agents | IDO1, IDO2, INMT | ATP6V1B1 3036/4885ATP6AP1 4182/4885HDAC4 766/4885 |
| US-20210402002-A1 | CONJUGATE | ST6GAL1, CSGALNACT1, FUT6 | ATP6V1B1 2049/4885ATP6AP1 4267/4885HDAC4 2398/4885 |
| US-20020173659-A1 | Indole derivatives for the treatment of osteoporosis | SOST, GHRHR, EBP | ATP6V1B1 2108/4885ATP6AP1 4110/4885HDAC4 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.